This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

The U.S. FDA-approved Mirabegron + Solifenacin for treating symptoms of an overactive bladder on June 28, 2012. It belongs to the family of Beta 3-adrenoceptor agonists and muscarinic receptor antagonists that helps to increase bladder capacity and reduce urinary urgency and frequency.

Mechanism of Action of undefined

Mirabegron + Solifenacin work together to improve bladder function. Mirabegron stimulates beta-3 adrenergic receptors, leading to the relaxation of bladder muscles, increased bladder capacity, and reduced urgency and frequency of urination. Solifenacin, on the other hand, blocks muscarinic receptors, relaxing the bladder muscles, reducing contractions, and increasing bladder capacity. This combined action helps improve overall bladder control and reduce urinary symptoms.

Uses of undefined

Mirabegron + Solifenacin treats symptoms associated with an overactive bladder, such as urgency incontinence (inability to control bladder emptying), sudden urination urges, and increased urinary frequency. 

undefined Drug administaration and Dosage available

Take the Mirabegron + Solifenacin as your physician advises. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

Warnings, Precautions and Side Effects of undefined


Mirabegron + Solifenacin should not be taken if you have allergies to Mirabegron, Solifenacin, or if you have high uncontrolled blood pressure. Before starting the treatment, inform your doctor if you have trouble emptying your bladder (urinary retention) or if you are taking specific medications for HIV, fungal or bacterial infections, or anticholinergic medicine. Avoid taking this medicine if you have a severe stomach or bowel condition such as toxic megacolon, muscle disease (myasthenia gravis), or glaucoma with progressive vision loss. It is recommended not to consume this medicine if you are undergoing kidney dialysis or if you have severe liver disease. 


Notify your doctor if you have liver or kidney problems. Your doctor may adjust your dose in such conditions. Also, inform your doctor if you have any heart conditions, such as abnormal ECG (QT prolongation) or taking medications that may cause it. This medicine is not advised to use in children under 18 years old. Inform your doctor if you are pregnant, planning to get pregnant, or think you may be pregnant or breastfeeding.  Report to your doctor if you have constipation, stomach tear (hiatus hernia), heartburn, or nervous disorder (autonomic neuropathy). 

Side Effects

The most common side effects of Mirabegron + Solifenacin are increased heart rate, nausea, constipation, diarrhea, dizziness, and urinary tract infection. Serious side effects while taking Mirabegron + Solifenacin are irregular heartbeat, sudden or throbbing headache, angioedema (swelling of the face, mouth, or throat), and elevated blood pressure. 

Word Of Advice

Patients with liver, heart, and kidney disorders should take Mirabegron + Solifenacin cautiously and inform the doctor about all the underlying medical conditions and medications that they consume. Avoid using this medication if you are intolerant to lactose sugar.

Do not stop Mirabegron + Solifenacin until your doctor advises. Do not double-dose the medicine to make up for a forgotten dose. Notify your doctor if you experience any serious side effects. Your medical professional will inform you if you need any dose adjustments. Contact your doctor for more information.

Frequently Asked Question


  1. Astellas Pharma Ltd, Electronic Medicines Compendium (EMC), [Revised on December 2022] [Accessed on 6th June 2023], Mirabegron + Solifenacin-TAB PL-Patient United Kingdom (Great Britain) en - TW366830 (
  2. Astellas Pharma US, Inc; [Revised on March 2021] [Accessed on 6th June 2023],label (
  3. Astellas Pharma Ltd, Electronic medicines compendium (EMC), [Revised on Dec 2022] [ Accessed on 20th June 2023],
  4. GlaxoSmithKline, US Food and Drug Administration, [Revised on April 2010] [ Accessed on 20th June 2023],
  5. Goodman & Gilman'sGilman's, The Pharmacological Basis of Therapeutics, Muscarinic receptor agonists and antagonists, 12th edition, 2011, 231.
  6. J. Goddard, A.N. Turner, Kidney and urinary tract disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 461-523.


The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.